Olga Samoilova

TL;DR: Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.

TL;DR: VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy, and appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse.

TL;DR: The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population and median progression- free survival was significantly longer in the ibrutinib plus obinutuzumab group than in the chlorambucil plus ob inutuzuab group.

TL;DR: In this article, patients were randomized 2:1 to venetoclax plus low-dose cytarabine (LDAC) or placebo (n = 68) in 28-day cycles, plus LDAC on days 1 to 10.

TL;DR: The HELIOS trial assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytics lymphoma and met the primary endpoint of progression-free survival.